UK's Trogenix raises £70m for cancer immunotherapy platform Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers.

#biotech #Trogenix #glioblastoma #GBM #4BIOCapital #drugdiscoveryplatform #Odysseus #syntheticsuperenhancers #SSEs #viralimmunotherapies #therapeuticpayloads #IL12 #AAV #SeriesAfinancing #Odysseusplatform #UKbiotechsector #venturecapitalinvestment #BIA #biotechfinancing
zurl.co/J20il